Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Neil K. Warma
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Beta
- -0.22
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 4.73
Financials
Revenue
$0.00-100.0%Net Income
$-11.73MEBITDA
$-11.73MFree Cash Flow
$-10.39MEPS (diluted)
$-1.28Shares Outstanding (diluted)
9.14M+7720.3%Operating Expenses
$12.27MCash & Debt
$53.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-39.72M | $-22.61 |
| 2024 | $0.00 | $2.78M | $2.75 |
| 2023 | $0.00 | $-17.51M | $-35.50 |
| 2022 | $0.00 | $-18.06B | $-60.25 |
| 2021 | $16.7K | $-11.98M | $-51.77 |
| 2020 | $1.6K | $-5.66M | $-29.74 |
| 2019 | $1.2K | $-7.40M | $-42.87 |
| 2018 | $348.74 | $-7.46M | $-46.75 |
| 2017 | $9.9K | $-4.79M | $-35.00 |
| 2016 | $2.0K | $-2.57M | $-22.75 |
| 2015 | $19.9K | $-1.53M | $-21.25 |
| 2014 | $344.5K | $-2.04M | $-63.12 |
| 2013 | $48.7K | $-2.04M | $-58.00 |
| 2012 | $49.5K | $-2.26M | $-60.90 |
Valuation
PMNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer Former senior Biogen and Roche executive brings deep experience across Alzheimer's clinical development, launch readiness, commercialization and global medical strategy
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
Promis Neurosciences Q2 Earnings Call Highlights Promis Neurosciences NASDAQ: PMN reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer's disease.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.27 per share
Typical surprise -18.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.28 vs $-1.38beat
- Mon, May 11$-1.26 vs $-1.06miss
- Mon, Mar 30$-4.11 vs $-4.22beat
- Wed, Nov 12$-6.00 vs $-3.75miss
- Wed, Aug 13$-7.25 vs $-5.50miss
- Mon, May 12$-5.25 vs $-3.00miss
Estimates and results for PMN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PMN officers and directors.
- Bought
- $18.9m
- Sold
- —
15 trades
1 trade
- Kaplan Johannebought
- Kirwin Patrick D.bought
- Williams Eugenebought
- Williams Eugenebought
- Williams Eugenebought
- Williams Eugenebought
- Kaplan Johannebought
- Abg Management Ltd.bought
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PMN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.